Lower costs and higher gross margin through mass production of new products
First written in FY2017-Q1. 15 of 24 entries say "Advanced", first in FY2019-Q1. Latest entry: FY2027-H1.
1 other company's latest entry also says "Other".
- FY2027-H1Decrease in gross profitAnnual report
「As a result, for the interim consolidated accounting period, revenue totaled ¥2,008 million, up 2.3% year on year, as sales from product rentals and other activities in Japan and APAC, as well as treatment services and other activities in the United States, increased. Gross profit totaled ¥1,176 million, down 3.7%.」
While revenue increased, gross profit fell 3.7% year on year due to higher cost of sales, marking a change from the previous trend of rising gross profit. - FY2026Decrease in gross profitAnnual report
「Gross profit was ¥2,265 million, down 4.5% year on year.」
Gross profit declined 4.5% from ¥2,373 million in the previous year to ¥2,265 million, marking a shift from the previous upward trend. - FY2025-H1Decrease in gross profitAnnual report
「As a result, during the interim consolidated accounting period, revenue was ¥2,143 million, up 1.9% year on year, due to an increase in medical services revenue in the United States and other revenue. Gross profit was ¥1,062 million, down 7.2%.」
While revenue increased, gross profit declined 7.2% from ¥1,144 million in the same period of the previous year to ¥1,062 million, marking a shift from the previous upward trend in gross profit. - FY2024AdvancedAnnual report
「Gross profit was ¥2,393 million, up 33.6% year on year.」
Increases in rental revenue from HAL and other products overseas and service revenue from group companies in Europe and the United States lifted gross profit from ¥1,791 million in the previous year to ¥2,393 million. - FY2024-Q3AdvancedAnnual report
「Gross profit was ¥1,742 million, up 17.6% year on year.」
Higher revenue from product rentals overseas and other sources drove gross profit up 17.6% from ¥1,482 million in the same period of the previous year to ¥1,742 million. - FY2024-Q2AdvancedAnnual report
「Gross profit was ¥989 million, up 15.7% year on year.」
Along with the increase in revenue, gross profit for the cumulative second quarter of the consolidated fiscal period rose 15.7% year on year to ¥1,144 million. - FY2024-Q1AdvancedAnnual report
「Gross profit was ¥566 million, up 15.4% year on year.」
Along with the increase in revenue, gross profit rose 15.4% from ¥490 million in the same period of the previous year to ¥566 million. - FY2023-Q3AdvancedAnnual report
「As a result, during the cumulative third quarter of the consolidated fiscal period, revenue was ¥2,374 million, up 76.3% year on year, and gross profit was ¥1,482 million, up 50.5%. This was due to substantial increases in medical services revenue in the United States and rental revenue to Asia and Europe.」
Increases in medical services revenue in the United States and rental revenue to Asia and Europe lifted gross profit to ¥1,482 million, up 50.5% year on year. - FY2023-Q2AdvancedAnnual report
「Gross profit was ¥989 million, up 59.8% year on year.」
Gross profit rose 59.8% year on year to ¥989 million, and the increase in gross profit continued. - FY2023-Q1AdvancedAnnual report
「Gross profit was ¥490 million, up 76.9% year on year.」
Along with the increase in revenue, gross profit rose 76.9% year on year to ¥490 million. - FY2022-Q3AdvancedAnnual report
「As a result, during the cumulative third quarter of the consolidated fiscal period, revenue was ¥1,347 million, up 8.0% year on year, and gross profit was ¥984 million, up 14.7%. This reflected growth in overseas revenue and the recovery of the RoboCare business and the German treatment services business, among other factors.」
Growth in overseas revenue and the recovery of the RoboCare business and German treatment services business, among other factors, lifted gross profit to ¥984 million, up 14.7% year on year. - FY2022-Q2Gross profit increaseAnnual report
「Gross profit was ¥619 million, up 12.0% year on year.」
Gross profit rose 12.0% year on year to ¥619 million, reversing the decline recorded in the same period of the previous year. - FY2022-Q1Gross profit recoveryAnnual report
「As a result, during the cumulative first quarter of the consolidated fiscal period, revenue was ¥380 million, up 5.9% year on year, and gross profit was ¥277 million, up 10.0%. This reflected the recovery of the RoboCare business and the German treatment services business, among other factors.」
Gross profit, which had declined in the same period of the previous year, rose to ¥277 million, up 10.0% year on year, marking a recovery from the previous declining trend. - FY2021-Q3Continued gross profit declineAnnual report
「As a result, during the cumulative third quarter of the consolidated fiscal period, revenue was ¥1,247 million, down 1.4% year on year, and gross profit was ¥858 million, down 6.8%. Although sales of goods and products increased, training service revenue and other revenue declined due to the impact of COVID-19.」
Although sales of goods and products and other revenue increased, the decline in training service revenue and other revenue caused gross profit to fall 6.8% year on year, and the decline in gross profit continued. - FY2021-Q2Continued gross profit declineAnnual report
「As a result, during the cumulative second quarter of the consolidated fiscal period, revenue was ¥794 million, down 3.5% year on year, and gross profit was ¥553 million, down 6.8%. Although sales of goods and products increased, training service revenue and other revenue declined due to the impact of COVID-19.」
Although sales of goods and products increased, the decline in training service revenue and other revenue resulted in gross profit falling 6.8% year on year, extending the decline in gross profit. - FY2021-Q1Gross profit declineAnnual report
「Although sales of goods and products increased, revenue was ¥359 million, down 8.8% year on year, due to declines in training service revenue and other revenue resulting from the impact of COVID-19. Gross profit was ¥252 million, down 11.8%.」
Revenue and gross profit declined year on year, marking a shift from the previous trend of improving gross profit. - FY2020AdvancedAnnual report
「Gross profit was ¥1,300 million, up 5.9% year on year, as the gross margin improved by 0.7 percentage points year on year to 72.5%.」
The full-year gross margin was 72.5%, up 0.7 percentage points from 71.8% in the previous fiscal year, and gross profit also increased to ¥1,300 million. - FY2020-Q3AdvancedAnnual report
「Gross profit was ¥921 million, up 4.0% year on year, as the gross margin improved by 1.0 percentage point year on year to 72.8%.」
The gross margin for the cumulative third quarter was 72.8%, up 1.0 percentage point year on year, and gross profit increased to ¥921 million. - FY2020-Q2AdvancedAnnual report
「Gross profit was ¥593 million, up 12.0% year on year, as the gross margin improved by 1.6 percentage points year on year to 72.1%.」
The gross margin for the cumulative second quarter improved by 1.6 percentage points year on year to 72.1%, and gross profit also rose to ¥593 million, up 12.0% year on year. - FY2020-Q1AdvancedAnnual report
「Gross profit was ¥286 million, up 23.2% year on year, as the gross margin improved by 3.4 percentage points year on year to 72.6%.」
The gross margin improved by 3.4 percentage points from 69.2% in the same period of the previous year to 72.6%, and gross profit also increased by 23.2% year on year. - FY2019-Q3AdvancedAnnual report
「Gross profit was ¥886 million, up 8.6% year on year, as the gross margin improved by 1.8 percentage points year on year to 71.8%.」
The gross margin improved by 1.8 percentage points year on year to 71.8%, and gross profit also increased by 8.6%. - FY2019-Q2AdvancedAnnual report
「Gross profit was ¥530 million, up 0.8% year on year, as the gross margin improved by 1.4 percentage points year on year to 70.4%.」
While revenue declined year on year, the gross margin improved by 1.4 percentage points to 70.4%, and gross profit increased to ¥530 million. - FY2019-Q1AdvancedAnnual report
「Gross profit was ¥232 million, down 4.3% year on year, as the gross margin improved by 0.8 percentage points year on year to 69.2%.」
While revenue declined, the gross margin rose to 69.2%, up 0.8 percentage points year on year. - FY2017-Q1First statedAnnual report
「As the cost-saving benefits of mass-producing new products kept cost of sales to ¥90.777 million, up 35.5% year on year, gross profit increased substantially to ¥181.153 million, up 76.6%, and the gross margin also rose significantly to 66.6%, up 6.1 percentage points.」
The company disclosed for the first time as a standalone performance item the cost reductions from mass production of new products and the improvement in gross margin to 66.6% in the first quarter.